Congestive Heart Failure (CHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Congestive Heart Failure (CHF) Market Outlook

Thelansis’s “Congestive Heart Failure (CHF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congestive Heart Failure treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Congestive Heart Failure (CHF) Overview

Heart failure is a complex clinical syndrome that occurs when the heart's functional or structural abnormalities impair its ability to adequately fill or eject blood into the systemic circulation, resulting in an inability to meet the body's circulatory demands. Congestive heart failure is caused by various factors, including structural and functional abnormalities of the heart and other triggering factors. Previously, most cases were attributed to coronary artery disease and myocardial infarction. However, coronary artery disease and diabetes mellitus have emerged as the predominant predisposing factors for heart failure. Other structural causes of congestive heart failure include hypertension, myocarditis, uncontrolled arrhythmia, valvular heart disease, and congenital heart disease. Heart failure is classified based on symptoms and the calculated left ventricular ejection fraction (LVEF). Left ventricular dysfunction-related heart failure is categorized into three types: heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mid-range ejection fraction (HFmrEF). The primary combination therapy for heart failure with reduced ejection fraction (HFrEF) involves the use of diuretics, a renin-angiotensin system inhibitor (such as an angiotensin receptor neprilysin inhibitor (ARNI), angiotensin-converting enzyme (ACE) inhibitor, or angiotensin II receptor blockers (ARB)), and a beta-blocker. Several diseases share similar clinical features of volume overload and dyspnea, which need to be considered in the differential diagnosis of heart failure. These include acute renal failure, acute respiratory distress syndrome (ARDS), cirrhosis, pulmonary fibrosis, nephrotic syndrome, and pulmonary embolism (PE). In patients with HFpEF, none of the current therapies have a definitive improvement in mortality or hospitalization. The mortality rate following hospitalization for heart failure is estimated to be approximately 10% at 30 days, 22% at 1 year, and 42% at 5 years. However, for patients classified as NYHA class IV, stage D heart failure, the mortality rate can exceed 50%.

• AHA Statistical Update estimated the prevalence of heart failure to be 6 million, approximately 1.8% of the US population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: